References
- De Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions-plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003;30:463-69 https://doi.org/10.1007/s00259-002-1107-8
-
Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G. Receptor radionuclide therapy with
$^{90}Y$ -[DOTA]0-Tyr3-octreotide ($^{90}Y$ -DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1038-46 -
Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with
$^{90}Y$ -DOTATOC,Tyr3-octreotide and$^{177}$ Lu-DOTA0,Tyr3-octreotate. J Nucl Med 2005;46(Suppl 1):83S-91S - Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. An overview of the peptide receptor radionuclide therapy with 3 different radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S-6S
-
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA. Radiolabeled somatostatin analog [
$^{177}$ LuDOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Gin Oncol 2005;23:2754-62 https://doi.org/10.1200/JCO.2005.08.066 - Virgolini I, Britton K, Buscornbe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55 https://doi.org/10.1053/snuc.2002.31565
- Reubi JC, Ma''ke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46(Suppl 1):67S-75S
-
Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L. Pivotal study of iodine
$^{131}$ I tositumomab for chemotherapy-refractory low-grade or transformed low grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28 https://doi.org/10.1200/JCO.2001.19.19.3918 -
Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al.
$^{131}$ I tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-49 https://doi.org/10.1056/NEJMoa041511 -
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II
$^{90}$ Y-Zevalin ($^{90}$ Y-ibritwnomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27:766-77 https://doi.org/10.1007/s002590000276 - Witzig TE, Flinn IW, Gordon LI, Vo K, Wiseman GA, Flinn IW, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-69 https://doi.org/10.1200/JCO.2002.11.017
-
Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF. Repeat treatment with
$^{131}$ I rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to$^{131}$ I rituximab. Annals of Oncology 2008;19:1629-33 https://doi.org/10.1093/annonc/mdn172 -
Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S et al. Re-treatment with
$^{131}$ I tositwnomab in patients with non-Hodgkin's lymphoma who had previously responded to$^{131}$ I tositwnomab. J Clin Oncol 2005;23:7985-93 https://doi.org/10.1200/JCO.2005.01.0892 -
Shah J, Wang W, Harrough VD, Saville W, Meredith R, Shen S, et al. Retreatment with
$^{90}$ Y ibritwnomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lynphoma 2007;48:1736-44 https://doi.org/10.1080/10428190701528517 - Klaus B and Hubert MT. Accurate dosimetry: an essential step towards good clinical practice in nuclear medicine. Nucl Med Commun 2005;26:581-6 https://doi.org/10.1097/01.mnm.0000169204.13754.e2
-
Ljungberg M, Sjo'' green K, Liu X, Frey E, Dewaraja Y, Strand SE. A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for
$^{131}$ I using Monte Carlo simulation. J Nucl Med 2002;43:1101-9 - Liu A, Wiliams LE, Wong JYC, Williams LE, Liu A, Wilczynski S et al. Monte Carlo assisted voxel source kernal method (MAVSK) for internal dosimetry. J Nucl Med Biol 1998;25:423-33 https://doi.org/10.1016/S0969-8051(98)00002-X
- Furhang EE, Chui CS, Sgouros G. A Monte Carlo approach to patient specific dosimetry. Med Phys 1996;23:1523 https://doi.org/10.1118/1.597882
- Yoriyaz H, Stabin MG, dos Santos A Monte Carlo MCNP-4B-hased absorbed dose distribution estimates for patient-specific dosimetry. J Nucl Med 2001;42:662
- DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of dosimetry in radioimmunotherapy planning and treatment dosing. Critical Rev Oncol Hematol 2001;39:203-18 https://doi.org/10.1016/S1040-8428(01)00109-3
-
Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with
$^{131}$ I MIBG. J Nucl Med 2001;42:1713-21 - DeNardo GL, Hartmann Siantar CL, DeNardo SJ. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm 2002;17:107-18 https://doi.org/10.1089/10849780252824127
-
Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole body emission tomography using
$^{18}$ F fluorodeoxyglucose for post treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has a higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33 - Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: role of FDG-PET in nodal staging. Radiology 1997;203:795-800 https://doi.org/10.1148/radiology.203.3.9169707
- Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Bur J Nucl Med 1998;25:721-8 https://doi.org/10.1007/s002590050275
-
Hong SP, Hahn JS, Lee JD, Bae SW, Youn MJ.
$^{18}F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and https://doi.org/10.3349/ymj.2003.44.5.779$^{67}$ Ga scan. Yonsei Med J 2003;44:779-86 - Carlo G, Kenneth R, Giuseppe LC. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007;57:125-34 https://doi.org/10.1016/j.lungcan.2007.03.020
-
Nestle U, Kremp S, Grosu AL. Practical integration of
$^{18}$ F-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 2006;81:209-25 https://doi.org/10.1016/j.radonc.2006.09.011 - Schoder H, Erdi YE, Chao K, Gonen M, Larson SM, Yeung HW. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. J Nucl Med 2004;45:559-66
- Paulino AC, Johnstone PA. FDG-PET in radiotherapy treatment planning: Pandora's box? Int J Radiat Oncol Biol Phys 2004;59:4-5 https://doi.org/10.1016/j.ijrobp.2003.10.045
- Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:78-86 https://doi.org/10.1016/j.ijrobp.2003.10.044
-
Giraud P, Grahek D, Montravers F, Carette MF, Deniaud-Alexandre E, Julia F, et al. CT and
$^{18}$ F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 2001;49:1249-57 https://doi.org/10.1016/S0360-3016(00)01579-0 - Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51-60 https://doi.org/10.1016/S0167-8140(01)00470-4
- Koral KF, Dewaraja Y, Clarke LA, Li J, Zasadny KR, Rommelfanger SG, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma; preliminary report. Cancer Biother Radiopharm 2000;15:301-3 https://doi.org/10.1089/cbr.2000.15.301
-
Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski MS. Accurate dosimetry in
$^{131}$ I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dese calculation. J Nucl Med 2005;46:840-9 - Joyce JM, Degirmenci B, Jacobs S, McCook B, Avril N. FDG PET CT assessment of treatment response after 90y ibritwnomab tiuxetan radioimmunotherapy. Clin Nucl Med 2005;30:564-8 https://doi.org/10.1097/01.rlu.0000170086.45627.99
-
Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin's lymphoma to
$^{131}$ I-anti-B1 radioimmunotherapy: evaluation with FDG-PET. J Nucl Med 2000;41:999-1005 -
Ulaner GA, Colletti PM, Conti PS. B-cell non-Hodgkin's lymphoma: PET/CT evaluation after
$^{90}$ Y-ibritwnomab tiuxetan radioimmunotherapy: initial experience. Radiology 2008;246:895-902 https://doi.org/10.1148/radiol.2463060588 -
Koral K, Francis I, Kroll S, Zasadny KR, Kaminski MS, Wahl RL. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received
$^{131}$ Y tositwnomab therapy. Cancer 2002;94(Suppl 1):1258-63 https://doi.org/10.1002/cncr.10294 -
Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with
$^{90}$ Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):92S-8S